2026-04-14T04:20:32Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1737592025-12-05T12:07:26Zcom_2072_1057col_2072_478916col_2072_478917

urn:hdl:2445/173759 Real-life effect of a microcrystalline tyrosine adjuvanted mite immunotherapy in patients with allergic rhinitis Roger, Albert Malet, Alfons Moreno, Victoria Parra, Antonio Gutierrez, Diego Lleonart Bellfill, Ramon Moreno, Francisco Valero, Antonio Navarro, Begoña Hinojosa, Belén Justicia, José L. Àcars Rinitis Mites Rhinitis Aim: Evaluate the effectiveness and safety of immunotherapy with Acarovac Plus((R)) in a 1-year prospective multicentered real-life study. Methods: A total of 118 adults with allergic rhinitis sensitized to Dermatophagoides received subcutaneous immunotherapy with Acarovac Plus. Treatment outcomes were evaluated at baseline, 6 months and 1 year after treatment initiation. Primary end point was the evolution of the combined symptom and medication score. Secondary end points included other effectiveness outcomes and measurement of product tolerability. Results: Acarovac Plus induced significant improvements in primary and secondary end points after 6 months compared with baseline. These differences persisted after 1 year of treatment (p < 0.001; baseline vs 1 year): combined symptom and medication score (1.60 vs 0.79). No serious adverse events were recorded. Conclusion: Acarovac Plus for 1 year was effective and well tolerated in a real-life setting. 2021-02-09T09:36:19Z 2021-02-09T09:36:19Z 2020-01-01 2021-02-08T10:12:28Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.2217/imt-2019-0205 Immunotherapy, 2020, vol. 12, num. 1, p. 53-62 https://doi.org/10.2217/imt-2019-0205 cc by-nc-nd (c) Roger et al., 2020 http://creativecommons.org/licenses/by-nc-nd/3.0/es/ info:eu-repo/semantics/openAccess Future Medicine Ltd. Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))